GlassScriptPhysician profile
Justine Kim
NPI 1821452582
$1,432.64
in general payments reported to CMS, 2019-2025
12 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $350 · 2023: $243 · 2024: $234 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.84 |
| Education | $130.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $331.74 | 2021-2025 | Femlyv, Intrarosa |
| Avion Pharmaceuticals | $238.98 | 2021-2023 | Balcoltra |
| Evofem Biosciences, INC. | $216.85 | 2021-2024 | Phexxi |
| Abbvie INC. | $136.40 | 2021-2023 | |
| Astellas Pharma US INC | $123.36 | 2024-2025 | Veozah |
| Scynexis, INC. | $116.05 | 2022 | |
| Pfizer INC. | $102.45 | 2023-2024 | |
| Biogen, INC. | $75.24 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $41.02 | 2021-2022 | |
| Organon LLC | $20.44 | 2024 | |
| Mayne Pharma Commercial LLC | $15.41 | 2022 | |
| Therapeuticsmd, INC. | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justine Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.